• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug

July 3, 2017 By Sarah Faulkner

IpsenIpsen (EPA:IPN) said today that Teijin Pharma Ltd. won approval from the Japanese Ministry of Health, Labor and Welfare for Ipsen’s Somatuline as a therapy for gastroenteropancreatic neuroendocrine tumors.

The subcutaneous drug was approved in Japan in 2012 for the treatment of acromegaly and pituitary gigantism.

The latest approval was supported by Ipsen’s pivotal Phase III trial which enrolled 204 patients with gastroenteropancreatic neuroendocrine tumors, as well as a 32-patient Phase II trial conducted by Teijin Pharma.

Somatuline is the 1st drug available in Japan as a therapy for pancreatic neuroendocrine tumors, according to Ipsen.

“We are pleased that Somatuline is now also available for Japanese patients suffering from gastrointestinal and pancreatic neuroendocrine tumors,” Harout Semerjian, exec VP and president of Ipsen’s specialty care international and global franchises, said in prepared remarks. “In line with our commitment to serve NET patients worldwide, this is a significant step after our partner Teijin launched Somatuline for the treatment of acromegaly and pituitary gigantism in Japan in January 2013.”

“It is our great pleasure to now have the capacity to provide a new therapeutic option to NET patients in Japan,” Akihisa Nabeshima, Teijin Pharma’s president, added. “We will continue to focus on drug discovery and improve the quality of life of patients by offering them new treatment options to fulfill unmet medical needs.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Ipsen, Teijin Pharma

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS